ATG4B and colorectal carcinoma: High levels of both ATG4B and pS383/392-ATG4B greatly increased the risk of mortality in both overall survival and disease-free survival of CRC patients (overall survival: AHR = 8.83, p < 0.001; disease-free survival: AHR = 6.50, p < 0.001, Table 1).